BR112012032182A2 - anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano. - Google Patents
anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano.Info
- Publication number
- BR112012032182A2 BR112012032182A2 BR112012032182A BR112012032182A BR112012032182A2 BR 112012032182 A2 BR112012032182 A2 BR 112012032182A2 BR 112012032182 A BR112012032182 A BR 112012032182A BR 112012032182 A BR112012032182 A BR 112012032182A BR 112012032182 A2 BR112012032182 A2 BR 112012032182A2
- Authority
- BR
- Brazil
- Prior art keywords
- cmv
- antibodies
- human
- protein
- high affinity
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003754 fetus Anatomy 0.000 abstract 1
- 230000003169 placental effect Effects 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35549910P | 2010-06-16 | 2010-06-16 | |
| PCT/US2011/040761 WO2011159938A2 (en) | 2010-06-16 | 2011-06-16 | High affinity human antibodies to human cytomegalovirus (cmv) gb protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012032182A2 true BR112012032182A2 (pt) | 2016-10-25 |
Family
ID=45348879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012032182A BR112012032182A2 (pt) | 2010-06-16 | 2011-06-16 | anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9017668B2 (enExample) |
| EP (1) | EP2582389B1 (enExample) |
| JP (2) | JP6055763B2 (enExample) |
| KR (1) | KR101900435B1 (enExample) |
| CN (1) | CN103221063B (enExample) |
| AU (1) | AU2011268277B2 (enExample) |
| BR (1) | BR112012032182A2 (enExample) |
| CA (1) | CA2839420C (enExample) |
| IL (1) | IL223665B (enExample) |
| RU (1) | RU2613421C2 (enExample) |
| WO (1) | WO2011159938A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2257571B1 (en) * | 2008-03-10 | 2015-03-04 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections |
| CN102892782B (zh) | 2009-12-23 | 2015-01-14 | 4-抗体股份公司 | 针对人类巨细胞病毒的结合成员 |
| KR101900435B1 (ko) * | 2010-06-16 | 2018-09-20 | 트렐리스 바이오싸이언스 인코포레이티드 | 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2018169785A2 (en) | 2017-03-13 | 2018-09-20 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Therapeutic antibodies to marburg virus |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CN118465272B (zh) * | 2019-12-04 | 2025-08-19 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642062B2 (en) | 1998-09-03 | 2003-11-04 | Trellis Bioinformatics, Inc. | Multihued labels |
| US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US7427469B2 (en) * | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
| RU2239453C2 (ru) * | 2002-12-03 | 2004-11-10 | Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" | Препарат иммуноглобулина человека против цитомегаловируса и способ его получения |
| US7595379B2 (en) | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
| US7413868B2 (en) | 2003-11-05 | 2008-08-19 | Trellis Bioscience, Inc. | Use of particulate labels in bioanalyte detection methods |
| WO2005118635A2 (en) * | 2004-06-03 | 2005-12-15 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| JPWO2007094423A1 (ja) | 2006-02-15 | 2009-07-09 | 株式会社イーベック | ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| JP2009531273A (ja) * | 2006-02-28 | 2009-09-03 | オンコセラピー・サイエンス株式会社 | 抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法 |
| PL2374818T3 (pl) * | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| WO2008008858A2 (en) | 2006-07-12 | 2008-01-17 | Trellis Bioscience, Inc. | Cellspot™ applications |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| CN100575361C (zh) * | 2007-04-28 | 2009-12-30 | 中国人民解放军第三军医大学野战外科研究所 | 抗人巨细胞病毒包膜糖蛋白b的人源化单链抗体 |
| US20110171233A1 (en) * | 2007-08-22 | 2011-07-14 | Ribovax Biotechnologies S.A. | Antibodies Against Human Cytomegalovirus (HCMV) |
| RU2364627C2 (ru) * | 2007-11-06 | 2009-08-20 | Власик Татьяна Николаевна | Экспрессионный вектор для синтеза белков в клетках млекопитающих |
| EP2262840A4 (en) | 2008-03-03 | 2012-08-08 | Dyax Corp | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS |
| EP2257571B1 (en) * | 2008-03-10 | 2015-03-04 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections |
| PL3009449T3 (pl) * | 2008-07-16 | 2018-09-28 | Institute For Research In Biomedicine | Przeciwciała neutralizujące ludzkie cytomegalowirusy i ich zastosowanie |
| KR101900435B1 (ko) * | 2010-06-16 | 2018-09-20 | 트렐리스 바이오싸이언스 인코포레이티드 | 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 |
-
2011
- 2011-06-16 KR KR1020137001220A patent/KR101900435B1/ko active Active
- 2011-06-16 EP EP11796460.1A patent/EP2582389B1/en active Active
- 2011-06-16 CA CA2839420A patent/CA2839420C/en active Active
- 2011-06-16 CN CN201180038472.0A patent/CN103221063B/zh not_active Expired - Fee Related
- 2011-06-16 BR BR112012032182A patent/BR112012032182A2/pt not_active IP Right Cessation
- 2011-06-16 US US13/162,497 patent/US9017668B2/en active Active
- 2011-06-16 RU RU2013101769A patent/RU2613421C2/ru not_active IP Right Cessation
- 2011-06-16 AU AU2011268277A patent/AU2011268277B2/en active Active
- 2011-06-16 JP JP2013515522A patent/JP6055763B2/ja active Active
- 2011-06-16 WO PCT/US2011/040761 patent/WO2011159938A2/en not_active Ceased
-
2012
- 2012-12-16 IL IL223665A patent/IL223665B/en active IP Right Grant
-
2015
- 2015-04-27 US US14/697,459 patent/US9688744B2/en active Active
-
2016
- 2016-10-07 JP JP2016198700A patent/JP2017038612A/ja active Pending
-
2017
- 2017-03-20 US US15/464,165 patent/US10030069B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2582389A2 (en) | 2013-04-24 |
| KR101900435B1 (ko) | 2018-09-20 |
| AU2011268277A2 (en) | 2013-07-25 |
| JP6055763B2 (ja) | 2016-12-27 |
| RU2013101769A (ru) | 2014-07-27 |
| JP2017038612A (ja) | 2017-02-23 |
| US9688744B2 (en) | 2017-06-27 |
| US10030069B2 (en) | 2018-07-24 |
| JP2013531991A (ja) | 2013-08-15 |
| CA2839420A1 (en) | 2011-12-22 |
| IL223665B (en) | 2020-01-30 |
| KR20130086036A (ko) | 2013-07-30 |
| EP2582389A4 (en) | 2014-01-08 |
| US20150252099A1 (en) | 2015-09-10 |
| CN103221063B (zh) | 2016-08-24 |
| RU2613421C2 (ru) | 2017-03-16 |
| WO2011159938A3 (en) | 2012-04-19 |
| US9017668B2 (en) | 2015-04-28 |
| AU2011268277B2 (en) | 2016-10-27 |
| US20120020980A1 (en) | 2012-01-26 |
| AU2011268277A1 (en) | 2013-01-31 |
| EP2582389B1 (en) | 2018-02-21 |
| CN103221063A (zh) | 2013-07-24 |
| WO2011159938A2 (en) | 2011-12-22 |
| CA2839420C (en) | 2023-06-13 |
| US20170204165A1 (en) | 2017-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012032182A2 (pt) | anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano. | |
| BR112018006995A2 (pt) | receptores anti-cd30 de antígeno quimérico | |
| EP3393536A4 (en) | DECELLULARIZED PLAZENTAMEMBRANE AND METHOD FOR THE PREPARATION AND USE | |
| EP3505620A4 (en) | 2D ORGANOID FOR INFECTIONS AND GROWTH OF HUMAN DIARRHOEVIRUS AND USE OF THE TWO-DIMENSIONAL ORGANOID | |
| MX2018010924A (es) | Células efectoras inmunitarias con edición genómica. | |
| PH12017500949A1 (en) | Human antibodies to influenza hemagglutinin | |
| CR20170019A (es) | Agentes inductores de apoptosis para eltratamiento de cáncer y enfermedades inmunes y autoinmunes | |
| WO2012001075A3 (en) | Immortalized avian cell lines | |
| EP2709453A4 (en) | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRUS DISEASES, CANCER AND DISEASES THROUGH INTRA-CELLULAR INFECTIONS | |
| ECSP12012020A (es) | Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes | |
| BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| CR20120631A (es) | Agentes inductores de apoptosis para el tratamiento del càncer y de enfermedades inmunes y autoinmunes | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| EP2909210A4 (en) | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES | |
| EP4048298A4 (en) | Preparation and use of therapeutic hydrogels | |
| EP2860188A4 (en) | POLYPEPTIDES AND ANTIBODIES FOR THE TREATMENT OF HBV INFECTIONS AND RELATED DISEASES | |
| ATE503769T1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
| BR112018008215A2 (pt) | artigo absorvente com canais e elementos elásticos de conformação | |
| EA201390663A1 (ru) | Универсальный гель против сухости влагалища с прямым и отсроченным эффектом | |
| BR112015021341A2 (pt) | anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos | |
| HUE058739T2 (hu) | Adipóz szövetbõl származó stromális õssejtek refrakter komplex perianális fisztulák kezelésében történõ alkalmazásra Crohn-betegségben | |
| BR112017013521A2 (pt) | terapia de antagonista do receptor de oxitocina na fase luteal para implantação e gravidez em mulheres sob tecnologias reprodutivas assistidas | |
| BR112014032682A2 (pt) | anticorpo monoclonal humano contra a proteína vp1 do vírus jc | |
| EA201791525A3 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
| ES2544153A1 (es) | Uso de un hidrolizado de caseína como agente antiviral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |